ZRC has constituted a Scientific Advisory Board comprising of world renowned scientists and clinicians to advice the group in its research endeavors.
Dr. Richard DiMarchi
Richard DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences, Professor and a former Chair of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He is a co-founder of Ambrx, Inc. and Marcadia Biotech. He serves as a board member to Ambrx, Marcadia, Isis Pharmaceuticals, and Alba Therapeutics. He is a scientific advisor to Epitome Biosciences, Kai Pharmaceuticals, Semafore Biotechnologies, and three venture funds; 5AM, TMP, and Twilight.
Professor DiMarchi is readily recognized for discovery and development of rDNA-derived Humalog® (LisPro-human insulin). This designer insulin represents the first demonstration that structurally altered rDNA-derived biosynthetic proteins can improve pharmacological performance without increasing the risk of an abnormal immunological response. As scientist and administrator Dr. DiMarchi also contributed to the commercial development of Humulin®, Humatrope®, Xigris®, rGlucagon®, Evista®, and Forteo®.
Dr. John Amatruda
Most recently Dr. Amatruda was Senior Vice President and Franchise Head for Diabetes and Obesity and a member of the Research Management Committee at Merck. Dr Amatruda graduated from Yale University, received his MD degree from the Medical College of Wisconsin and did his internship and residency in Internal Medicine and Fellowship in Endocrinology and Metabolism at The Johns Hopkins Hospital. He is board certified in internal medicine and Endocrinology and Metabolism. ( For more details,click here)
Dr. Kapil Dhingra
Kapil Dhingra has served as a member of Micromet’s Board of Directors since February 2009. In June 2008, Dr. Dhingra founded KAPital Consulting, LLC, a healthcare consulting firm. From 1999 to 2008, Dr. Dhingra served in positions of increasing responsibility at Hoffmann-La Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Hoffmann-La Roche, Dr. Dhingra worked as a Senior Clinical Research Physician with Eli Lilly and Company. . ( For more details,click here)
Dr. Robert R. Henry
Dr. Henry is an internationally renowned clinical investigator and scientist. Dr. Henry is Professor of Medicine at the University of California San Diego and the Chief of Endocrinology at the VA San Diego Healthcare System. ( For more details,click here)
Dr. Charles F. Burant, MD, PhD
Dr. Charles F. Burant, MD, PhD is Professor of Internal Medicine at the University of Michigan Health System in Ann Arbor, Michigan. He currently is the Robert C. and Veronica Atkins Professor of Metabolism and directs the Michigan Metabolomics and Obesity Center. His research interests are in the areas of the molecular and cellular biology of insulin resistance and the effect of insulin resistance on ß-cell function as well as lipid and glucose metabolism. His clinical interests are focused on type 2 diabetes, insulin resistance, and the metabolic syndrome. Dr Burant is an Associate Editor for the American Journal of Physiology-Endocrinology and Metabolism. He is active in the American Diabetes Association, serving on the Research Policy Committee and the Board of Directors of the Research Foundation.
( For more details,click here)
Dr. Thomas A. Baillie
Dr. Thomas A. Baillie is Dean of the School of Pharmacy and Vice Provost for Strategic Initiatives at the University of Washington in Seattle, WA. He was born in Scotland and educated at the University of Glasgow, where he earned B.Sc. (Hons) and Ph.D. degrees in Chemistry. He also holds an M.Sc. degree in Biochemistry from the University of London and was awarded the degree of D.Sc. in Chemistry from the University of Glasgow in 1992.
Following postdoctoral research at the Karolinska Institute in Stockholm, Sweden, Dr. Baillie held successive faculty positions at the University of London, University of California San Francisco, and University of Washington. He then joined Merck Research Laboratories in West Point, PA, where he was Global Vice President of Drug Metabolism & Pharmacokinetics until 2008, when he returned to the University of Washington to assume his present responsibilities.
Dr. Baillie’s research interests center on the application of mass spectrometry and allied techniques to mechanistic studies on the metabolism of foreign compounds, with particular emphasis on the generation of chemically-reactive, potentially toxic products of biotransformation.
In addition to the Scientific Advisory Board, ZRC also has well-experienced advisors to help the research team in making appropriate decisions on various targets and research areas of focus to the company.